China humanoid robot IPOs are slowing as regulators scrutinize soaring valuations and revenue tied to state-backed projects. The shift follows a volatile first month for Unitree Robotics shares and tests whether investor enthusiasm for embodied AI is running ahead of commercial demand.

 

The reported scrutiny centers on four issues:

  • Unitree shares fell 55% from their post-listing peak.
  • Some robot revenue comes from government-supported training centers.
  • Regulators are questioning whether those orders represent independent demand.
  • At least six humanoid-robot companies are preparing public offerings.

 

China Humanoid Robot IPOs Face Informal Slowdown

Reuters reported that Chinese regulators have used informal “window guidance” to hold back some humanoid-robot listings. One source described the market as effectively frozen for now, while another stressed that there is no formal ban and called the action a sector-specific slowdown.

 

That distinction matters. The China Securities Regulatory Commission has not announced a prohibition, and it did not respond to Reuters’ request for comment. The reported action instead raises the approval threshold while bankers and issuers face closer questions about valuation, customers and the durability of revenue.

 

Deep Robotics, X Square Robot and AGIBOT are among the companies preparing to list, according to Reuters. The companies did not answer questions about whether regulators had slowed their plans, leaving individual timetables uncertain even as scrutiny tightens across the sector.

 

Unitree’s Debut Became the Market Test

Unitree Robotics helped trigger the reassessment after a dramatic Shanghai debut. Its shares rose more than fivefold before retreating 55% from their peak, a swing that turned one of China’s most celebrated robotics listings into a warning about speculative pricing.

 

The company makes humanoid and quadruped robots and had become a symbol of China’s effort to lead physical AI. Its public-market volatility gave regulators a visible example of how scarce listings, strategic-policy support and retail enthusiasm can produce prices that move faster than operating fundamentals.

 

Background Reading

 

State-Backed Revenue Draws Scrutiny

Regulators are focusing on whether robot companies can sustain revenue generated through local-government-backed projects. These include data-collection centers where machines are trained and joint ventures in which local authorities may provide 80% to 90% of the initial investment, according to a person cited by Reuters.

 

Such projects can produce early orders, help companies meet listing thresholds and support private valuations. They do not necessarily demonstrate that factories, logistics operators or households are buying robots at scale without government assistance, which is the commercial test public investors ultimately need.

 

The same source estimated that some valuations could fall 60% to 70% if revenue linked to data-collection centers were excluded. That estimate is not an official regulatory calculation, but it illustrates why due diligence is moving from technical demonstrations toward customer concentration, repeat orders and cash generation.

 

Private markets are already adjusting. Reuters reported that some robotics projects had taken valuation cuts of 30% to 50%, while investors increasingly demand evidence of deployments and order volumes before accepting premiums attached to the embodied-AI label.

 

Beijing Still Treats Embodied AI as Strategic

The tighter IPO stance does not represent a retreat from robotics. China’s 2026 government work report placed advanced technology and future industries at the center of economic policy, while the submitted report specifically identified embodied AI among the fields China intends to develop.

 

That creates a deliberate tension: officials want capital to keep funding strategic technologies without allowing policy enthusiasm to obscure weak demand or inflated prices. The current scrutiny therefore looks more like an attempt to improve listing quality than an effort to stop humanoid development.

 

Mainland Chinese companies have raised $148.9 billion through share sales and convertible offerings so far in 2026, up 59% from the same period a year earlier, LSEG data cited by Reuters showed. Technology companies accounted for 41% of that total, giving regulators a broader reason to preserve confidence in new listings.

 

For robot makers, the next financing phase will depend less on choreographed demonstrations and more on measurable factory use, paid deployments and repeat customers. Companies that can separate independent revenue from policy-supported pilot projects should retain access to capital, while those built mainly around valuation momentum may face longer waits or lower prices.